Department of Vermont Health Access
Pharmacy Benefits Management Program
DUR Board Meeting Agenda

September 10, 2013   6:00 – 8:30 p.m.

1. Executive Session   6:00 - 6:30
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes   6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates   6:35 - 6:45
   - Updates

4. Medical Director Update   6:45 - 6:50
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings   6:50 - 7:05
   - Pediatric Antipsychotic Medications

6. RetroDUR/DUR   7:05 – 7:20
   - Discussion of Possible Topics for Coming Year

7. Clinical Update: Drug Reviews   7:20 – 8:00
   (Public comment prior to Board action)
   Abbreviated New Drug Reviews
   - Abilify® Maintena (aripiprazole) Intramuscular Injection
   - Lotemax® (loteprrednol) Ophthalmic Gel
   - Uceris® (budesonide) ER Oral Tablets

   Full New Drug Reviews
   - Gattex® (teduglutide) Subcutaneous Injection
   - Juxtapid® (lomitapide) Oral Capsule
   - Kynamro® ( mipomersen) Subcutaneous Injection
   - Nesina*, Oseni® & Kazano® (alogliptin, alogliptin/pioglitazone &
     alogliptin/metformin) Oral Tablets
   - Signifor® (pasireotide) Subcutaneous Injection
   - Vascepa® (icosapent ethyl) Oral Capsule

8. Therapeutic Drug Classes – Periodic Review   8:00 – 8:10
   (Public comment prior to Board action)
   Class review documents available on DVHA web site 09/10/2013 @ Noon
   - Antivirals: Oral
   - Antivirals: Topical
9. **New Managed Therapeutic Drug Classes** 8:10–8:15
   (Public comment prior to Board action)
   - Epinephrine Auto-injector

10. **Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** 8:15–8:25
    (Public comment prior to Board action)
    - Crinone®
    - Makena®
    - Second Generation Cephalosporins

11. **General Announcements** 8:25–8:30
    **Selected FDA Safety Alerts**
    - Acetaminophen: Drug Safety Communication - Association with Risk of Serious Skin Reactions
    - Gilenya: Drug Safety Communication - Possible PML Case in Europe
    - Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
    - Zyprexa Relprevv (Olanzapine Pamoate): Drug Safety Communication - FDA Investigating Two Deaths Following Injection

12. **Adjourn** 8:30